Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | HRH4 | Q9H3N8 | 6/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 8/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | RBP4 | P02753 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23779102 | 0.88 | POLB (0.48) | POLBSMN1; SMN2HDAC6HRH4HRH3 | |
| SCHEMBL23779075 | 0.86 | POLB (0.53) | POLBSMN1; SMN2HDAC6HRH4HRH3 | |
| SCHEMBL24320723 | 0.86 | HDAC6 (0.50) | POLBSMN1; SMN2HDAC6HRH4HRH3 | |
| SCHEMBL23779053 | 0.86 | POLB (0.47) | POLBSMN1; SMN2HDAC6HRH4HRH3 | |
| SCHEMBL24319780 | 0.85 | HDAC6 (0.51) | POLBSMN1; SMN2HDAC6HRH4HRH3 | |
| SCHEMBL24320729 | 0.85 | HDAC6 (0.51) | POLBSMN1; SMN2HDAC6HRH4HRH3 | |
| SCHEMBL23779101 | 0.84 | POLB (0.51) | POLBSMN1; SMN2HDAC6HRH4HRH3 | |
| SCHEMBL23779123 | 0.84 | POLB (0.51) | POLBSMN1; SMN2HDAC6HRH4HRH3 | |
| SCHEMBL23779054 | 0.84 | HDAC6 (0.48) | POLBSMN1; SMN2HDAC6HRH4HRH3 | |
| SCHEMBL24319791 | 0.83 | HDAC6 (0.47) | POLBSMN1; SMN2HDAC6HRH4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220081444-A1 | 6,7-DIHYDRO-4H-PYRAZOLO[1,5-A]PYRAZINE INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) | AICURIS GMBH & CO. KG (DE) | 2022-03-17 | — | — | US | disclosed |
| US-20220081444-A1 | 6,7-DIHYDRO-4H-PYRAZOLO[1,5-A]PYRAZINE INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) | AICURIS GMBH & CO. KG (DE) | 2022-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220081444-A1 | 6,7-DIHYDRO-4H-PYRAZOLO[1,5-A]PYRAZINE INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) | HCCS, CDK2, BRD4 | POLB 536/4885SMN1; SMN2 4877/4885HDAC6 897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.